Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: SSRI Active Clear all

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions: Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sexual Dysfunction, Major Depressive Disorder
Interventions: Vilazodone, Sertraline; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Charlottesville, Virginia

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more

Conditions: Sexual Dysfunction
Interventions: Viveve System; Device
Lead sponsor: Michael Krychman, MD; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: COVID-19, Olfactory Disorder, Parosmia
Interventions: Fluvoxamine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo oral tablet; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 60 Years to 90 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: PTSD, Alcohol Use Disorder
Interventions: Sertraline, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bipolar Depression
Interventions: Escitalopram, Celecoxib, Placebo; Drug
Lead sponsor: Loyola University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Depression
Interventions: Zolpidem, Placebo; Drug · Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 21 Years to 40 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder
Interventions: 6(S)-5-MTHF (a Medical Food); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 11
States / cities: San Diego, California • Chicago, Illinois • New Orleans, Louisiana + 8 more

Conditions: Bipolar Disorder, Alcohol Dependence
Interventions: Placebo, Quetiapine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Creatine, Placebo; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Autistic Disorder
Interventions: citalopram hydrobromide, placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more

Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions: LDAEP, Placebo, sertraline; Diagnostic Test · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Charleston, South Carolina

Conditions: Treatment Outcome
Interventions: Vortioxetine, Escitalopram, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 53
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more

Conditions: Panic Disorder
Interventions: quetiapine XR, placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sexual Dysfunction
Interventions: Exercise; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions: Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bipolar Disorder, Bipolar Depression, Depression
Interventions: quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity; Drug · Behavioral
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • National City, California + 25 more

Conditions: Major Depressive Disorder
Interventions: EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo; Drug
Lead sponsor: Euthymics BioScience, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 43
States / cities: Arcadia, California • Beverly Hills, California • National City, California + 39 more

Conditions: Depression
Interventions: S-adenosyl-l-methionine, Escitalopram, Placebo; Drug
Lead sponsor: Maurizio Fava, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Major Depressive Disorder With Psychotic Features
Interventions: Quetiapine, escitalopram, Sertraline, Citalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obsessive Compulsive Disorder
Interventions: Minocycline, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 8 Years to 20 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

Mechanisms of Antidepressant Non-Response in Late-Life Depression

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Proton MRS Study of SSRI-Zolpidem Interactions

A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)

Quetiapine for Bipolar Disorder and Alcohol Dependence

Contact: Developing New Clinical Management Strategies

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

Predicting SSRI Efficacy in Veterans With PTSD

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

Efficacy of Exercise for Sexual Side Effects of Antidepressants

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Seroquel in Bipolar Depression Versus SSRI

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD